Johnson & Johnson

What's your position on ?
Why are you ish?
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • May 6, 2013, 12:56 PM

    Johnson & Johnson (JNJ -1%) dips today on the back of its announcement over the weekend that it's recalling all bottles of Children's Tylenol it made and sold in South Korea, after finding high levels of acetaminophen, it's main ingredient. The company says it traced the problem to the failure of machines that fill the bottles at the end of manufacturing runs. Once they failed, some of the remaining bottles were filled by hand, leading to the improper concentrations. JNJ says the health risk is remote, and it hasn't received any reports of harm. The recall doesn't affect any products sold in the U.S.

    | May 6, 2013, 12:56 PM | 1 Comment
  • Apr. 26, 2013, 3:42 PM
    Looking for dividend picks, Marketwatch screens the S&P 1,500 for 1) Stock trades at less than a 17x PE 2) Dividend yield 20% or more higher than S&P 500 3) Raised dividend at least 5 times in last 5 years 4) S&P Quality Rank of B+ or better. The winners: T, AVA, BAX, CAH, CAG, ED, JNJ, LG, TAP, RAI, SCG, UVV, WR, XEL.
    | Apr. 26, 2013, 3:42 PM | 1 Comment
  • Apr. 25, 2013, 1:59 PM
    Johnson & Johnson (JNJ) declares $0.66/share quarterly dividend, 8.2% increase from prior dividend of $0.61. Forward yield 3.10%. For shareholders of record May 28. Payable June 11. Ex-div date May 23. (PR)
    | Apr. 25, 2013, 1:59 PM | 4 Comments
  • Apr. 18, 2013, 10:00 AM

    Johnson & Johnson (JNJ) will realize an after-tax gain of $213M from the sale of 82M ADSs in Elan back to the Irish company. J&J had tendered 107.4M shares in Elan's repurchase program . (PR)

    | Apr. 18, 2013, 10:00 AM
  • Apr. 18, 2013, 9:40 AM

    Johnson & Johnson (JNJ) tenders 107.4M Elan (ELN) shares at the strike price of $11.25 in the latter's $1B stock buyback. The total number of shares tendered is 239.7M, of which Elan plans to purchase 76%. Elan is retiring 14.8% of the stock in issue as part of the repurchase plan. (PR)

    | Apr. 18, 2013, 9:40 AM
  • Apr. 17, 2013, 3:09 AM

    Johnson & Johnson (JNJ) has won the second lawsuit over its ASR hip implant, with a jury in Chicago ruling that the company didn't inappropriately market the all-metal device, which the plaintiff argued J&J knew was flawed. The verdict follows a decision in LA to award $8.3M against the company. J&J faces 10,000 lawsuits over ARS, including a class-action case in Ohio.

    | Apr. 17, 2013, 3:09 AM
  • Apr. 16, 2013, 7:52 AM
    Johnson & Johnson (JNJ): Q1 EPS of $1.44 beats by $0.04. Revenue of $17.5B (+8.5% Y/Y) beats by $0.04B. (PR)
    | Apr. 16, 2013, 7:52 AM
  • Apr. 16, 2013, 12:05 AM
    Notable earnings before Tuesday’s open: AMTD, BLK, CMA, GS, GWW, JNJ, KO, NTRS, USB, WWW
    | Apr. 16, 2013, 12:05 AM
  • Apr. 15, 2013, 5:30 PM
    Notable earnings before Tuesday’s open: AMTD, BLK, CMA, GS, GWW, JNJ, KO, NTRS, USB, WWW
    | Apr. 15, 2013, 5:30 PM
  • Apr. 11, 2013, 10:29 AM

    Pharmacyclics (PCYC +1.7%) gets a bump higher this morning after announcing its Phase III clinical trial using Ibrutinib versus Chlorambucil to treat chronic lymphocytic leukemia and small lymphocyctic lymphoma has enrolled its fifth patient. The enrollment subsequently triggers a fourth $50M milestone payment obligation from JNJ's Janssen Biotech, who is collaborating with PCYC on Ibrutinib in oncology. On Monday, the drug was granted a 3rd "Breakthrough Therapy Designation" by the FDA.

    | Apr. 11, 2013, 10:29 AM | 1 Comment
  • Apr. 10, 2013, 1:37 PM

    Jefferies raises its price targets on big pharma names Pfizer (PFE +2.6%) ($33), Merck (MRK +2.7%) ($48), Johnson & Johnson (JNJ +0.7%) ($85), Eli Lilly (LLY +1.4%) ($44), Bristol-Myers Squibb (BMY +0.5%) ($45), AbbVie (ABBV +1.2%) ($50), and Abbot Laboratories (ABT +1.1%) ($42). "We remain positive on pharmaceuticals," Jefferies says, "valuation is attractive for most stocks." 

    | Apr. 10, 2013, 1:37 PM | 6 Comments
  • Apr. 8, 2013, 1:02 PM

    Johnson & Johnson's (JNJ -1.6%) slips today on a downgrade to Neutral at JPMorgan, saying the stock has reached a "trading premium." Last June, JP notes, the stock was trading at a 5% discount to the "sum-of-its-parts." Now, after a 30% run, the shares trade at an 8% premium, and despite an improvement in the fundamentals, the stock is poised to plateau, at least over the near term. The firm did however, ratchet-up its price target to $83 from $77.

    | Apr. 8, 2013, 1:02 PM
  • Apr. 4, 2013, 4:25 PM
    Johnson and Johnson (JNJ) subsidiary Cordis Corp notches a legal victory as the U.S. Court of Appeals for the Federal Circuit overturns a ruling ordering a payment of $482M to radiologist Bruce Saffran. Saffran alleges patent infringement in connection with Cordis' Cypher stents. 
    | Apr. 4, 2013, 4:25 PM
  • Apr. 4, 2013, 4:45 AM
    The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK).
    | Apr. 4, 2013, 4:45 AM | 5 Comments
  • Apr. 3, 2013, 11:51 AM

    Astex Pharmaceuticals (ASTX +12.5%) gets a pop from RBC today, who initiated coverage with an Outperform and a $9 price target, calling it an "undiscovered gem." The firm says the ASTX could have a blockbuster in its pipeline with its experimental blood cancer drug, SGI-110, which is thought to be a safer and more effective version of an already approved therapy it licenses to Eisai (ESALY.PK) and JNJ. ASTX owns all the rights to SGI-110, giving it big upside potential if it gets approved. Additionally, the company reported earlier that it plans to present "significant data" at the AACR annual meeting on Saturday.

    | Apr. 3, 2013, 11:51 AM
  • Apr. 1, 2013, 9:09 AM

    Medical products maker Covidien (COV) says it was awarded $176M as a federal court ruled several patents were infringed by Johnson & Johnson's (JNJ) Ethicon Endo-Surgery unit and its Harmonic line of ultrasonic surgical products.

    | Apr. 1, 2013, 9:09 AM
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.